APA

Hagiwara N., Watanabe M., Iizuka-Ohashi M., Yokota I., Toriyama S., Sukeno M., Tomosugi M., Sowa Y., Hongo F., Mikami K., Soh J., Fujito A., Miyashita H., Morioka Y., Miki T., Ukimura O. & Sakai T. (20190909). Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. : Cancer letters.

Chicago

Hagiwara Nobuhisa, Watanabe Motoki, Iizuka-Ohashi Mahiro, Yokota Isao, Toriyama Seijiro, Sukeno Mamiko, Tomosugi Mitsuhiro, Sowa Yoshihiro, Hongo Fumiya, Mikami Kazuya, Soh Jintetsu, Fujito Akira, Miyashita Hiroaki, Morioka Yukako, Miki Tsuneharu, Ukimura Osamu and Sakai Toshiyuki. 20190909. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. : Cancer letters.

Harvard

Hagiwara N., Watanabe M., Iizuka-Ohashi M., Yokota I., Toriyama S., Sukeno M., Tomosugi M., Sowa Y., Hongo F., Mikami K., Soh J., Fujito A., Miyashita H., Morioka Y., Miki T., Ukimura O. and Sakai T. (20190909). Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. : Cancer letters.

MLA

Hagiwara Nobuhisa, Watanabe Motoki, Iizuka-Ohashi Mahiro, Yokota Isao, Toriyama Seijiro, Sukeno Mamiko, Tomosugi Mitsuhiro, Sowa Yoshihiro, Hongo Fumiya, Mikami Kazuya, Soh Jintetsu, Fujito Akira, Miyashita Hiroaki, Morioka Yukako, Miki Tsuneharu, Ukimura Osamu and Sakai Toshiyuki. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. : Cancer letters. 20190909.